Table 1.
Characteristics of targeted anticancer medication in the intervention group and comparison group
| No | Generic name | Launch time in China | Indication |
| Intervention group | |||
| 1 | Rituximab | April 2000 | Lymphoma |
| 2 | Trastuzumab | September 2002 | Breast cancer; stomach cancer |
| 3 | Bortezomib | February 2005 | Multiple myeloma; lymphoma |
| 4 | Recombinant Human Endostatin | September 2005 | Lung cancer |
| 5 | Erlotinib | April 2006 | Lung cancer |
| 6 | Sorafenib | September 2006 | Liver cancer; kidney cancer; thyroid cancer |
| 7 | Nimotuzumab | April 2008 | Nasopharynx cancer |
| 8 | Bevacizumab | February 2010 | Colorectal cancer; lung cancer |
| 9 | Fulvestrant | June 2010 | Breast cancer |
| 10 | Lapatinib | January 2013 | Breast cancer |
| 11 | Everolimus | January 2013 | Brain cancer; kidney cancer; pancreatic neuroendocrine tumor |
| 12 | Lenalidomide | January 2013 | Multiple myeloma |
| 13 | Apatinib | October 2014 | Stomach cancer |
| 14 | Chidamide | December 2014 | Lymphoma |
| 15 | Abiraterone | May 2015 | Prostate cancer |
| Comparison group | |||
| 1 | Cetuximab | July 2006 | Colorectal cancer |
| 2 | Sunitinib | October 2007 | Kidney cancer; stomach cancer; pancreatic neuroendocrine tumor |
| 3 | Pegaspargase | January 2009 | Leukaemia |
| 4 | Nilotinib | July 2009 | Leukaemia |
| 5 | Crizotinib | January 2013 | Lung cancer |
| 6 | Axitinib | April 2015 | Kidney cancer |